Vaxart (VXRT) director buys shares at $0.393 and $0.405
Vaxart, Inc. (VXRT) reported an insider share purchase by a director.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vaxart, Inc. (VXRT) reported an insider share purchase by a director. On 11/17/2025, the director bought 23,217 shares of common stock in an open-market transaction at $0.393 per share and a further 16,783 shares at $0.405 per share. After these purchases, the director beneficially owned 96,566 shares, held directly. The filing notes the person’s role as a director and confirms the report is filed by a single reporting person.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 23,217 | $0.393 | $9K |
| Purchase | Common Stock | 16,783 | $0.405 | $7K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Vaxart (VXRT) report in this Form 4?
What is the relationship of the reporting person to Vaxart (VXRT)?
Were any derivative securities reported in this Vaxart (VXRT) Form 4?
Was the Vaxart (VXRT) Form 4 filed for one or multiple reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.